New intra-articular injection route will expand the suite of drug delivery options available in GastroPlus®

Simulations Plus Enters into New Research Collaboration Agreement with the FDA
Center for Veterinary Medicine to apply GastroPlus® to assess product bioequivalence in canines

Simulations Plus Reports Third Quarter FY2019 Financial Results
Record quarter as revenues grow 16%, 9MoFY19 revenues up 13%
Board of Directors announces quarterly dividend of $0.06 per share

Simulations Plus Upgrades PKPlus™
Enhancements include improved data handling and command line functionality

Simulations Plus Sets Date for 3rd Quarter 2019 Earnings Release and Conference Call
Conference Call to be on Wednesday, July 10, 2019, at 4:15 PM ET

DILIsym Releases NAFLDsym® Version 2A
Substantial update of NAFLD drug efficacy software offers a broad range of pathophysiology and over a thousand simulated patients for testing

Simulations Plus Upgrades Flagship GastroPlus
User- and collaboration-driven functionality in version 9.7 expands the science of local and systemic exposure

Cognigen Launches KIWI Version 4.0
Exciting New Features to its Pharmacometric Communication and Collaboration Platform

PMDA Adds Licenses of GastroPlus®
Japanese government organization to train reviewers to efficiently analyze PBPK model submissions

U.S. FDA Renews DILIsym Software Licenses
U.S. FDA Remains Committed to Streamline & Accelerate Drug Development using Model-Informed Drug Development (MIDD) technology

Simulations Plus to Present at B. Riley FBR Investor Conference on May 22, 2019
Shawn O’Connor, chief executive officer, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22, at 10:30 a.m. (PDT) in Room 8.

Lisa LaVange, PhD, Appointed to Board of Directors of Simulations Plus
Brings 35+ Years of Industry and Regulatory Expertise to Board

FDA Purchases Bundle of ADMET Predictor® Licenses
Center for Tobacco Products incorporates machine learning platform to assist toxicology research

Simulations Plus Releases ADMET Predictor® Version 9.5
New machine learning models and novel analysis methods address customer requests

Simulations Plus Reports Record Second Quarter FY2019 Revenue
Quarterly Revenues Up 15%; Board of Directors Announces Quarterly Dividend of $0.06 Per Share

Simulations Plus Sets Date for 2nd Quarter 2019 Earnings Release and Conference Call
Conference Call to be on Tuesday, April 9, 2019, at 4:15 PM ET

DILIsym Awarded $1.5 Million Phase II NIH Grant
Phase II Award of NIH Fast Track SBIR Grant for Drug-induced Kidney Injury Software, RENAsym™, Funds Development Over Next 20 Months

Simulations Plus Releases DDDPlus™ Version 6
New models for in vitro systems lead to improved inputs for GastroPlus® simulations

DILIsym Services Inc. Initiates Development of IPFsym™
New idiopathic pulmonary fibrosis QSP platform to enable more efficient drug development